These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 35789987)

  • 1. The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review.
    Witkowski M; Moreno SI; Fernandes J; Johansen P; Augusto M; Nair S
    Pharmacoeconomics; 2022 Aug; 40(8):751-776. PubMed ID: 35789987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes.
    Younossi Z; Aggarwal P; Shrestha I; Fernandes J; Johansen P; Augusto M; Nair S
    JHEP Rep; 2022 Sep; 4(9):100525. PubMed ID: 36039144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study.
    O'Hara J; Finnegan A; Dhillon H; Ruiz-Casas L; Pedra G; Franks B; Morgan G; Hebditch V; Jönsson B; Mabhala M; Reic T; Van Thiel I; Ratziu V; Romero-Gomez M; Bugianesi E; Schattenberg JM; Anstee QM
    JHEP Rep; 2020 Oct; 2(5):100142. PubMed ID: 32775976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements.
    Johansen P; Howard D; Bishop R; Moreno SI; Buchholtz K
    Pharmacoeconomics; 2020 May; 38(5):485-497. PubMed ID: 31919793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy.
    Petta S; Ting J; Saragoni S; Degli Esposti L; Shreay S; Petroni ML; Marchesini G;
    Nutr Metab Cardiovasc Dis; 2020 Jun; 30(6):1014-1022. PubMed ID: 32423665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database.
    Terai S; Buchanan-Hughes A; Ng A; Lee IH; Hasegawa K
    J Gastroenterol; 2021 Mar; 56(3):274-284. PubMed ID: 33496858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis.
    Schattenberg JM; Lazarus JV; Newsome PN; Serfaty L; Aghemo A; Augustin S; Tsochatzis E; de Ledinghen V; Bugianesi E; Romero-Gomez M; Bantel H; Ryder SD; Boursier J; Leroy V; Crespo J; Castera L; Floros L; Atella V; Mestre-Ferrandiz J; Elliott R; Kautz A; Morgan A; Hartmanis S; Vasudevan S; Pezzullo L; Trylesinski A; Cure S; Higgins V; Ratziu V
    Liver Int; 2021 Jun; 41(6):1227-1242. PubMed ID: 33590598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand.
    Phisalprapa P; Prasitwarachot R; Kositamongkol C; Hengswat P; Srivanichakorn W; Washirasaksiri C; Treeprasertsuk S; Charatcharoenwitthaya P; Chaiyakunapruk N
    BMC Gastroenterol; 2021 Mar; 21(1):135. PubMed ID: 33765931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients.
    C Gordon S; Fraysse J; Li S; Ozbay AB; Wong RJ
    Am J Gastroenterol; 2020 Apr; 115(4):562-574. PubMed ID: 31833859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018.
    Morgan A; Hartmanis S; Tsochatzis E; Newsome PN; Ryder SD; Elliott R; Floros L; Hall R; Higgins V; Stanley G; Cure S; Vasudevan S; Pezzullo L
    Eur J Health Econ; 2021 Jun; 22(4):505-518. PubMed ID: 33751289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic burden of respiratory syncytial virus infection in adults: a systematic literature review.
    Grace M; Colosia A; Wolowacz S; Panozzo C; Ghaswalla P
    J Med Econ; 2023; 26(1):742-759. PubMed ID: 37167068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH).
    Povsic M; Wong OY; Perry R; Bottomley J
    Adv Ther; 2019 Jul; 36(7):1574-1594. PubMed ID: 31065991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates and Kuwait.
    Sanai FM; Al Khathlan A; Al Fadhli A; Jazzar AS; Hashim AM; Mansour E; Abaalkhail F; Hasan F; Al Mudaiheem H; Al Quraishi H; Bottomley J; Alswat KA; Al Ghamdi M; Farghaly M; Fathy M; Awad N; Mohamed O; Kozma S; Al-Hamoudi W; Al-Jedai A
    Hepatol Int; 2021 Aug; 15(4):912-921. PubMed ID: 33822317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology and disease burden of non-alcoholic steatohepatitis in greater China: a systematic review.
    Zou H; Ge Y; Lei Q; Ung COL; Ruan Z; Lai Y; Yao D; Hu H
    Hepatol Int; 2022 Feb; 16(1):27-37. PubMed ID: 35098442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Burden of Nonalcoholic Steatohepatitis: A Systematic Review of Epidemiology Studies.
    Tapper EB; Fleming C; Rendon A; Fernandes J; Johansen P; Augusto M; Nair S
    Gastro Hep Adv; 2022; 1(6):1049-1087. PubMed ID: 39131247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
    Younossi ZM; Golabi P; de Avila L; Paik JM; Srishord M; Fukui N; Qiu Y; Burns L; Afendy A; Nader F
    J Hepatol; 2019 Oct; 71(4):793-801. PubMed ID: 31279902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases.
    Wong RJ; Kachru N; Martinez DJ; Moynihan M; Ozbay AB; Gordon SC
    J Clin Gastroenterol; 2021 Nov-Dec 01; 55(10):891-902. PubMed ID: 32815873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.
    Quek J; Chan KE; Wong ZY; Tan C; Tan B; Lim WH; Tan DJH; Tang ASP; Tay P; Xiao J; Yong JN; Zeng RW; Chew NWS; Nah B; Kulkarni A; Siddiqui MS; Dan YY; Wong VW; Sanyal AJ; Noureddin M; Muthiah M; Ng CH
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):20-30. PubMed ID: 36400097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic burden of COVID-19 for employers and employees in the United States.
    Sell H; Schaible K; Gouveia-Pisano JA; Yehoshua A; Malhotra D; Di Fusco M; Cha-Silva AS; Andersen KM; Nicholls L; Landi SN; Rolland C; Judy J
    J Med Econ; 2024; 27(1):267-278. PubMed ID: 38294896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study.
    Haldar D; Kern B; Hodson J; Armstrong MJ; Adam R; Berlakovich G; Fritz J; Feurstein B; Popp W; Karam V; Muiesan P; O'Grady J; Jamieson N; Wigmore SJ; Pirenne J; Malek-Hosseini SA; Hidalgo E; Tokat Y; Paul A; Pratschke J; Bartels M; Trunecka P; Settmacher U; Pinzani M; Duvoux C; Newsome PN; Schneeberger S;
    J Hepatol; 2019 Aug; 71(2):313-322. PubMed ID: 31071367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.